Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?
Payaningal R. Somanath
Abstract
PerspectivesIs targeting Akt a viable option to treat advanced-stage COVID-19 patients?Payaningal R. SomanathPayaningal R. SomanathClinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, GeorgiaCharlie Norwood VA Medical Center, Augusta, GeorgiaGeorgia Cancer Center, Vascular Biology Center and Department of Medicine, Augusta University, Augusta, GeorgiaPublished Online:25 Jun 2020https://doi.org/10.1152/ajplung.00124.2020This is the final version - click for previous versionMoreFiguresReferencesRelatedInformationSectionsGRANTSDISCLOSURESAUTHOR CONTRIBUTIONSAUTHOR NOTESPDF (102 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookXLinkedInWeChat One of the primary reasons for high mortality in the advanced-stage coronavirus disease-2019 (COVID-19) patients is the uncontrolled inflammation in the lungs leading to acute respiratory distress syndrome (ARDS). Controlling the pathological inflammation in the ARDS lungs without compromising the immune system's fight against the virus is indeed a daunting task. In this situation, an appropriate therapeutic target would be the one that will not only reverse the damaging inflammation and promote resolution but also helps to check the root cause of the virus infection. Akt is a potential therapeutic target for the advanced-stage COVID-19 patients; its inhibition will potentially suppress the pathological inflammation, cytokine storm, fibroproliferation, and platelet activation associated with COVID-19, and at the same time prevent scarring and promote resolution in injured lungs. As pharmacological inhibition of Akt has also been reported to inhibit angiotensin-converting enzyme 2 (ACE2) expression, a receptor for the virus entry into the lung cells, targeting Akt for COVID-19 looks a viable option. Severe acute respiratory syndrome (SARS), an acute respiratory distress syndrome (ARDS) caused by the coronavirus-2 (SARS-CoV-2), is the primary reason for high mortality associated with coronavirus disease-2019 (COVID-19) (25). The prolonged asymptomatic incubation period in COVID-19 patients ranging between 1 and 14 days (5.1 days median) is a major bottleneck in its early detection and preventing it from infecting the lungs of some patients (12). Additionally, comorbidities such as diabetes and hypertension (10, 24) and a history of medications such as angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors (9) further worsens the COVID-19 associated ARDS. The effect of comorbidities (14) and the use of cardiovascular medications (19) are believed to be due to the increased expression of ACE2, a putative receptor for SARS-CoV-2 (23). As current treatment options for ARDS are very limited (21, 22), treating advanced COVID-19 patients is a bigger challenge due to the reasons above. Early detection and preventing a lung infection would be the most desirable approach to treat COVID-19 patients. Although some COVID-19 patients present early symptoms, many patients harboring SARS-CoV-2 remain on a long asymptomatic period and are undetected until complications arise (10, 12). Having a large population suffering from metabolic diseases and hypertension in Western countries (17), the potential risk of COVID-19 associated ARDS is also higher. Hence, it is not always possible to cure COVID-19 patients before severe lung infection takes hold. The next obvious question is, how do we treat advanced-stage COVID-19 patients with lung infections? One potential option would be to target ACE2 or pathways promoting ACE2 expression or activation. Alternately, COVID-19 patients can also be treated by engineered peptides, antibodies, or compounds to disrupt or prevent the interaction between SARS-CoV-2 spike protein and ACE2 (23) that will prevent reinfections and limit the lung damage. A better option to manage advanced-stage COVID-19 patients would be a drug that can not only suppress inflammation but also promote the resolution of lung injury and prevent scarring (Fig. 1).Fig. 1.Akt inhibition will increase the number of CD4+/FoxP3+/CD103+/CTLA4+ effector regulatory T cells (Tregs) in the acute respiratory distress syndrome (ARDS) lung to suppress inflammation and promote injury resolution. In the ARDS lung, reduced Akt activity in conventional T cells will promote their differentiation to effector Tregs, limiting inflammation and scar formation, and promoting vascular regeneration and wound resolution, revealing the potential therapeutic benefits of Akt inhibitors such as triciribine and MK2206 to treat ARDS in advanced-stage coronavirus disease-2019 (COVID-19) patients.Download figureDownload PowerPoint The phosphoinositide 3 (PI3)-kinase/Akt pathway promotes inflammation in several disease states (8). Whereas genetic deletion of Akt1 gene reduced inflammation and improved cardiac function in mice following myocardial ischemia (13, 16), pharmacological Akt inhibition suppressed inflammation in mice, myofibroblast differentiation, and prevented vascular rarefaction to halt pulmonary fibrosis progression (1, 2). Furthermore, whereas Akt1 deficiency in macrophages resulted in reduced foam cell formation (13), inhibition of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) leading to Akt activation in the regulatory T cells (Tregs) promoted inflammation (18). Adoptive transfer of Tregs has demonstrated to suppress fibroproliferation and improve injury resolution in an animal model of experimental lung injury (6, 15), suggesting that increasing the number of Tregs in ARDS lungs would be an ideal strategy to treat COVID-19 patients in the advanced stages. However, the pharmacological means to increase the number of Tregs in ARDS lung was not available until we recently demonstrated that the number of the effector (activated) Tregs in the advanced stages of bacterial endotoxin-induced experimental lung injury in mouse lungs can be increased by Akt inhibition with compounds such as triciribine and MK2206, promoting injury resolution and recovery (3). Whereas ACE2 has been implicated in pulmonary arterial hypertension (7) and lung inflammation (11), Akt inhibition with MK2206 and triciribine has been reported to ameliorate the pathological effects of ACE2 in hepatic steatosis (4). However, a link between the Akt pathway and ACE2 activation in COVID-19 patients needs to be investigated. Although the host PI3-kinase/Akt pathway is utilized by the viruses in general for its survival and replication (5, 20), this has not been demonstrated in the case of the SARS-CoV-2 virus replication in the lung epithelial cells. On the contrary, an adverse effect of Akt suppression by promoting the SARS-CoV-2 virus replication in the patient lung epithelial cells also cannot be ruled out. Nevertheless, pharmacological inhibition of the Akt pathway using inhibitors such as triciribine and MK2206, alone or in combination with the currently evolving standard of care, provides potential treatment options for COVID-19 patients with ARDS. Based on the preclinical observations from non-COVID-19 lung disease research, Akt suppression is expected to increase Tregs in the lungs of COVID-19 patients, in turn, suppressing inflammation and fibroproliferation, promoting the resolution of injury, and preventing vascular pruning in the lungs as a result of SARS-CoV-2 infection. This, however, needs further experimental validation in a suitable preclinical COVID-19 model such as the non-human primates before clinical trials are conducted in COVID-19 patients.GRANTS This work was supported in part by National Heart, Lung, and Blood Institute Grant R01HL103952 and National Center for Advancing Translational Sciences Grant UL1TR002378.DISCLOSURES No conflicts of interest, financial or otherwise, are declared by the author.AUTHOR CONTRIBUTIONS P.R.S prepared figure; drafted manuscript; edited and revised manuscript; and approved final version of manuscript.AUTHOR NOTESCorrespondence: P. R. Somanath ([email protected]). Download PDF Previous Back to Top Next FiguresReferencesRelatedInformationREFERENCES1. Abdalla M, Goc A, Segar L, Somanath PR. Akt1 mediates α-smooth muscle actin expression and myofibroblast differentiation via myocardin and serum response factor. J Biol Chem 288: 33483–33493, 2013. doi:10.1074/jbc.M113.504290. Crossref | PubMed | Web of Science | Google Scholar2. Abdalla M, Sabbineni H, Prakash R, Ergul A, Fagan SC, Somanath PR. The Akt inhibitor, triciribine, ameliorates chronic hypoxia-induced vascular pruning and TGFβ-induced pulmonary fibrosis. Br J Pharmacol 172: 4173–4188, 2015. doi:10.1111/bph.13203. Crossref | PubMed | Web of Science | Google Scholar3. Artham S, Verma A, Alwhaibi A, Adil MS, Manicassamy S, Munn DH, Somanath PR. Delayed Akt suppression in the lipopolysaccharide-induced acute lung injury promotes resolution that is associated with enhanced effector regulatory T cells. Am J Physiol Lung Cell Mol Physiol 318: L750–L761, 2020. doi:10.1152/ajplung.00251.2019. Link | Web of Science | Google Scholar4. Cao X, Yang F, Shi T, Yuan M, Xin Z, Xie R, Li S, Li H, Yang JK. Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis activates Akt signaling to ameliorate hepatic steatosis. Sci Rep 6: 21592, 2016. doi:10.1038/srep21592. Crossref | PubMed | Web of Science | Google Scholar5. Dunn EF, Connor JH. HijAkt: the PI3K/Akt pathway in virus replication and pathogenesis. Prog Mol Biol Transl Sci 106: 223–250, 2012. doi:10.1016/B978-0-12-396456-4.00002-X. Crossref | PubMed | Web of Science | Google Scholar6. Garibaldi BT, D'Alessio FR, Mock JR, Files DC, Chau E, Eto Y, Drummond MB, Aggarwal NR, Sidhaye V, King LS. Regulatory T cells reduce acute lung injury fibroproliferation by decreasing fibrocyte recruitment. Am J Respir Cell Mol Biol 48: 35–43, 2013. doi:10.1165/rcmb.2012-0198OC. Crossref | PubMed | Web of Science | Google Scholar7. Guignabert C, de Man F, Lombès M. ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad. Eur Respir J 51: 1800848, 2018. doi:10.1183/13993003.00848-2018. Crossref | PubMed | Web of Science | Google Scholar8. Hawkins PT, Stephens LR. PI3K signalling in inflammation. Biochim Biophys Acta 1851: 882–897, 2015. doi:10.1016/j.bbalip.2014.12.006. Crossref | PubMed | Web of Science | Google Scholar9. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181: 271–280.e8, 2020. doi:10.1016/j.cell.2020.02.052. Crossref | PubMed | Web of Science | Google Scholar10. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497–506, 2020. doi:10.1016/S0140-6736(20)30183-5. Crossref | PubMed | Web of Science | Google Scholar11. Jia H. Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease. Shock 46: 239–248, 2016. doi:10.1097/SHK.0000000000000633. Crossref | PubMed | Web of Science | Google Scholar12. Jiang X, Rayner S, Luo MH. Does SARS-CoV-2 has a longer incubation period than SARS and MERS? J Med Virol 92: 476–478, 2020. doi:10.1002/jmv.25708. Crossref | PubMed | Web of Science | Google Scholar13. Kerr BA, Ma L, West XZ, Ding L, Malinin NL, Weber ME, Tischenko M, Goc A, Somanath PR, Penn MS, Podrez EA, Byzova TV. Interference with akt signaling protects against myocardial infarction and death by limiting the consequences of oxidative stress. Sci Signal 6: ra67, 2013. doi:10.1126/scisignal.2003948. Crossref | PubMed | Web of Science | Google Scholar14. Li G, He X, Zhang L, Ran Q, Wang J, Xiong A, Wu D, Chen F, Sun J, Chang C. Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19. J Autoimmun. In press. doi:10.1016/j.jaut.2020.102463. Crossref | PubMed | Web of Science | Google Scholar15. Lin S, Wu H, Wang C, Xiao Z, Xu F. Regulatory T cells and acute lung injury: cytokines, uncontrolled inflammation, and therapeutic implications. Front Immunol 9: 1545, 2018. doi:10.3389/fimmu.2018.01545. Crossref | PubMed | Web of Science | Google Scholar16. Ma L, Kerr BA, Naga Prasad SV, Byzova TV, Somanath PR. Differential effects of Akt1 signaling on short- versus long-term consequences of myocardial infarction and reperfusion injury. Lab Invest 94: 1083–1091, 2014. doi:10.1038/labinvest.2014.95. Crossref | PubMed | Web of Science | Google Scholar17. Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep 20: 12, 2018. doi:10.1007/s11906-018-0812-z. Crossref | PubMed | Web of Science | Google Scholar18. Sharma MD, Shinde R, McGaha TL, Huang L, Holmgaard RB, Wolchok JD, Mautino MR, Celis E, Sharpe AH, Francisco LM, Powell JD, Yagita H, Mellor AL, Blazar BR, Munn DH. The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment. Sci Adv 1: e1500845, 2015. doi:10.1126/sciadv.1500845. Crossref | PubMed | Web of Science | Google Scholar19. Singh AK, Gupta R, Misra A. Comorbidities in COVID-19: outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes Metab Syndr 14: 283–287, 2020. doi:10.1016/j.dsx.2020.03.016. Crossref | PubMed | Web of Science | Google Scholar20. Soares JA, Leite FG, Andrade LG, Torres AA, De Sousa LP, Barcelos LS, Teixeira MM, Ferreira PC, Kroon EG, Souto-Padrón T, Bonjardim CA. Activation of the PI3K/Akt pathway early during vaccinia and cowpox virus infections is required for both host survival and viral replication. J Virol 83: 6883–6899, 2009. doi:10.1128/JVI.00245-09. Crossref | PubMed | Web of Science | Google Scholar21. Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. N Engl J Med 377: 1904–1905, 2017. doi:10.1056/NEJMra1608077. Crossref | PubMed | Web of Science | Google Scholar22. Umbrello M, Formenti P, Bolgiaghi L, Chiumello D. Current concepts of ARDS: a narrative review. Int J Mol Sci 18: 64, 2016. doi:10.3390/ijms18010064. Crossref | PubMed | Web of Science | Google Scholar23. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181: 281–292.e6, 2020. doi:10.1016/j.cell.2020.02.058. Crossref | PubMed | Web of Science | Google Scholar24. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323: 1239, 2020. doi:10.1001/jama.2020.2648. Crossref | PubMed | Web of Science | Google Scholar25. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395: 1054–1062, 2020. doi:10.1016/S0140-6736(20)30566-3. Crossref | PubMed | Web of Science | Google Scholar CollectionsAPS Cross-Journal CollectionsCoronavirus-Related Papers Cited ByIdentification of GRB10 Expression as a Novel Blood Biomarker for Prognosis of COVID-19 Severity19 October 2023Attention Mechanism-Based Graph Neural Network Model for Effective Activity Prediction of SARS-CoV-2 Main Protease Inhibitors: Application to Drug Repurposing as Potential COVID-19 Therapy14 November 2023 | Journal of Chemical Information and Modeling, Vol. 63, No. 22Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐214 May 2023 | MedComm, Vol. 4, No. 3Triciribine attenuates pathological neovascularization and vascular permeability in a mouse model of proliferative retinopathy1 Jun 2023 | Biomedicine & Pharmacotherapy, Vol. 162An integrated in-silico Pharmaco-BioInformatics approaches to identify synergistic effects of COVID-19 to HIV patients1 Mar 2023 | Computers in Biology and Medicine, Vol. 155Recombinant ACE2 protein protects against acute lung injury induced by SARS-CoV-2 spike RBD protein9 June 2022 | Critical Care, Vol. 26, No. 1Estrogen hormone is an essential sex factor inhibiting inflammation and immune response in COVID-198 June 2022 | Scientific Reports, Vol. 12, No. 1Live and let die: signaling AKTivation and UPRegulation dynamics in SARS-CoVs infection and cancer3 October 2022 | Cell Death & Disease, Vol. 13, No. 10An overview of possible pivotal mechanisms of Genistein as a potential phytochemical against SARS‐CoV‐2 infection: A hypothesis22 July 2022 | Journal of Food Biochemistry, Vol. 46, No. 10Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions1 August 2022 | MedComm, Vol. 3, No. 3Insights into potential mechanisms of asthma patients with COVID-19: A study based on the gene expression profiling of bronchoalveolar lavage fluid1 Jul 2022 | Computers in Biology and Medicine, Vol. 146The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-191 Mar 2022 | Drug Discovery Today, Vol. 27, No. 3Recent Progress in the Development of Opaganib for the Treatment of Covid-191 July 2022 | Drug Design, Development and Therapy, Vol. Volume 16The Sphingosine Kinase 2 Inhibitor Opaganib Protects Against Acute Kidney Injury in Mice1 November 2022 | International Journal of Nephrology and Renovascular Disease, Vol. Volume 15Targeting the PI3K/Akt/mTOR pathway: A therapeutic strategy in COVID-19 patients1 Dec 2021 | Immunology Letters, Vol. 240Integrative web-based analysis of omics data for study of drugs against SARS-CoV-224 May 2021 | Scientific Reports, Vol. 11, No. 1COVID-19-Associated acute respiratory distress syndrome (CARDS): Mechanistic insights on therapeutic intervention and emerging trends1 Dec 2021 | International Immunopharmacology, Vol. 101Akt‐independent effects of triciribine on ACE2 expression in human lung epithelial cells: Potential benefits in restricting SARS‐CoV2 infection24 February 2021 | Journal of Cellular Physiology, Vol. 236, No. 9Development and validation of LC/MS/MS method for Triciribine and its monophosphate metabolite in plasma and RBC: Application to mice pharmacokinetic studies1 Jun 2021 | Journal of Chromatography B, Vol. 1174Nanotechnology to the Rescue: Treatment Perspective for the Immune Dysregulation Observed in COVID-1931 March 2021 | Frontiers in Nanotechnology, Vol. 3Attenuation of acute and chronic inflammation using compounds derived from plants6 October 2020 | Experimental Biology and Medicine, Vol. 246, No. 4Regulatory T cells in COVID-191 Jan 2021 | Aging and disease, Vol. 12, No. 7Akt-Fas to Quell Aberrant T Cell Differentiation and Apoptosis in Covid-1921 December 2020 | Frontiers in Immunology, Vol. 11 More from this issue > Volume 319Issue 1July 2020Pages L45-L47 https://doi.org/10.1152/ajplung.00124.2020PubMed32519895History Received 1 April 2020 Accepted 4 June 2020 Published online 25 June 2020 Published in print 1 July 2020 Metrics Downloaded 2,235 times See more details Posted by 6 X users 66 readers on Mendeley 26 CITATIONS 26 Total citations 6 Recent citations 8.81 Field Citation Ratio 1.39 Relative Citation Ratio publications25supporting0mentioning31contrasting0Smart Citations250310Citing PublicationsSupportingMentioningContrastingView CitationsSee how this article has been cited at scite.aiscite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made. See more details Posted by 6 X users 66 readers on Mendeley We recommendARDS in the Time of Corona: Context and PerspectiveNorbert F Voelkel, American Journal of Physiology - Lung Cellular and Molecular Physiology, 2022Can phytotherapy with polyphenols serve as a powerful approach for the prevention and therapy tool of novel coronavirus disease 2019 (COVID-19)?Emile Levy, American Journal of Physiology - Endocrinology and Metabolism, 2020ACE2 and a Traditional Chinese Medicine Formula NRICM101 Could Alleviate the Inflammation and Pathogenic Process of Acute Lung InjuryCheng-Han Lin, Physiology, 2024Urgent reconsideration of lung edema as a preventable outcome in COVID-19: inhibition of TRPV4 represents a promising and feasible approachWolfgang M. Kuebler, American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020SARS-CoV-2, ACE2 expression, and systemic organ invasionUsman M. Ashraf, Physiological Genomics, 2021Top 10 academic progress on traditional Chinese medicine in 2022 China Association of Chinese Medicine, Science of Traditional Chinese Medicine, 2023Complementary and alternative medicine during COVID-19 pandemic: What we have done Chang-quan Ling, Journal of Integrative Medicine, 2022The coronavirus disease-19 pandemic and acute coronary syndrome: a specific impact in the elderly Viktor Čulić, Journal of Geriatric Cardiology, 2022Qingjin Huatan decoction attenuates lipopolysaccharide-induced acute lung injury in mice by controlling platelet-associated formation of neutrophil extracellula... Shunli Xiao, Science of Traditional Chinese Medicine, 2023COVID-19: cardiovascular manifestations—a review of the cardiac effects Taha Hatab, Journal of Geriatric Cardiology, 2022Powered by Privacy policyGoogle Analytics settings